Key Points
- This research aims to evaluate the effectiveness of aldosterone antagonists, particularly spironolactone, in patients with resistant hypertension.
- Investigated patients diagnosed with resistant hypertension who were on multiple antihypertensive medications.
- Administered spironolactone to measure its effect on blood pressure reduction.
- Assessed patient demographics, comorbidities, and medication adherence.
- Spironolactone effectively reduced blood pressure by an average of 4.6 mmHg systolic (p=0.006) and 1.8 mmHg diastolic (p=0.07).
- The study revealed that patient factors, such as age and gender, influenced the choice of spironolactone treatment.
- The overall effectiveness of spironolactone was less impressive compared to other non-controlled studies.
Structured PICO
Do aldosterone antagonists reduce blood pressure in patients with resistant hypertension?
PPopulationPatients with resistant hypertension (defined as elevated blood pressure in spite of treatment with three different antihypertensive agents)
IInterventionAldosterone antagonists (e.g., spironolactone) added to multidrug antihypertensive regimens
OOutcomeBlood pressure reductionsurrogate
Aldosterone antagonists like spironolactone appear effective for lowering blood pressure in resistant hypertension, though the evidence base is limited by small, largely uncontrolled studies.
Limitations
- Poorly characterized patient populations in reviewed studies
- Differing definitions of resistant hypertension across studies
- Lack of control groups in most studies
- Selection bias regarding age and gender in some cohorts